Swedes win on the EU patent but other tough questions pass to Spain
This article was originally published in Scrip
Executive Summary
When the Swedes assumed the six-month presidency of the EU Council of Ministers in July, they vowed that by the end of the year they would have made progress on a number of areas of direct relevance to the biopharmaceutical industry. To their credit, they have managed to get the member states to agree on contentious issues such as the single EU patent, but success in other areas has proved more elusive.